Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

to related objects

Abstract: Cerebrospinal fluid (CSF) tau (total tau, T‐tau), neurofilament light (NFL), and neurogranin (Ng) are potential biomarkers for neurodegeneration in Alzheimer's disease (AD). It is unknown whether these biomarkers provide similar or complementary information in AD. We examined 93 patients with AD, 187 patients with mild cognitive impairment, and 109 controls. T‐tau, Ng, and NFL were all predictors of AD diagnosis. Combinations improved the diagnostic accuracy (AUC 85.5% for T‐tau, Ng, and NFL) compared to individual biomarkers (T‐tau 80.8%; Ng 71.4%; NFL 77.7%). T‐tau and Ng were highly correlated (ρ = 0.79, P < 0.001) and strongly associated with β‐amyloid (Aβ) pathology, and with longitudinal deterioration in cognition and brain structure, primarily in people with Aβ pathology. NFL on the other hand was not associated with Aβ pathology and was associated with cognitive decline and brain atrophy independent of Aβ. T‐tau, Ng, and NFL provide partly independent information about neuronal injury and may be combined to improve the diagnostic accuracy for AD. T‐tau and Ng reflect Aβ‐dependent neurodegeneration, while NFL reflects neurodegeneration independently of Aβ pathology.

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource

Language: Englisch

Bibliographic citation: Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease ; volume:8 ; number:10 ; year:2016 ; pages:1184-1196 ; extent:13
EMBO molecular medicine / European Molecular Biology Organization ; 8, Heft 10 (2016), 1184-1196 (gesamt 13)

Creator: Mattsson-Carlgren, Niklas
Insel, Philip S.
Palmqvist, Sebastian
Portelius, Erik
Zetterberg, Henrik
Weiner, Michael
Blennow, Kaj
Hansson, Oskar

DOI: 10.15252/emmm.201606540

URN: urn:nbn:de:101:1-2022111007132479423308

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:26 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Mattsson-Carlgren, Niklas
Insel, Philip S.
Palmqvist, Sebastian
Portelius, Erik
Zetterberg, Henrik
Weiner, Michael
Blennow, Kaj
Hansson, Oskar

Other Objects (12)

Fluid biomarkers in Alzheimer’s disease – current concepts

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

Serum and cerebrospinal fluid neurofilament light chain in patients with central nervous system infections caused by varicella-zoster virus

Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the App NL−F/NL−F knock-in mouse model of Alzheimer’s disease

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment

Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer’s disease

Acute-Phase Neurofilament Light and Glial Fibrillary Acidic Proteins in Cerebrospinal Fluid Predict Long-Term Outcome After Severe Traumatic Brain Injury

Publisher Correction: Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies

Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies

Fluid biomarkers in Alzheimer’s disease – current concepts

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

Serum and cerebrospinal fluid neurofilament light chain in patients with central nervous system infections caused by varicella-zoster virus

Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the App NL−F/NL−F knock-in mouse model of Alzheimer’s disease

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment

Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer’s disease

Acute-Phase Neurofilament Light and Glial Fibrillary Acidic Proteins in Cerebrospinal Fluid Predict Long-Term Outcome After Severe Traumatic Brain Injury

Publisher Correction: Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies

Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies

Fluid biomarkers in Alzheimer’s disease – current concepts

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

Serum and cerebrospinal fluid neurofilament light chain in patients with central nervous system infections caused by varicella-zoster virus

Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the App NL−F/NL−F knock-in mouse model of Alzheimer’s disease

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment

Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer’s disease

Acute-Phase Neurofilament Light and Glial Fibrillary Acidic Proteins in Cerebrospinal Fluid Predict Long-Term Outcome After Severe Traumatic Brain Injury

Publisher Correction: Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies

Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Fluid biomarkers in Alzheimer’s disease – current concepts

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

Serum and cerebrospinal fluid neurofilament light chain in patients with central nervous system infections caused by varicella-zoster virus

Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the App NL−F/NL−F knock-in mouse model of Alzheimer’s disease

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment

Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer’s disease

Acute-Phase Neurofilament Light and Glial Fibrillary Acidic Proteins in Cerebrospinal Fluid Predict Long-Term Outcome After Severe Traumatic Brain Injury

Publisher Correction: Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies

Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies

Fluid biomarkers in Alzheimer’s disease – current concepts

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

Serum and cerebrospinal fluid neurofilament light chain in patients with central nervous system infections caused by varicella-zoster virus

Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the App NL−F/NL−F knock-in mouse model of Alzheimer’s disease

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment

Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer’s disease

Acute-Phase Neurofilament Light and Glial Fibrillary Acidic Proteins in Cerebrospinal Fluid Predict Long-Term Outcome After Severe Traumatic Brain Injury

Publisher Correction: Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies

Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies

Fluid biomarkers in Alzheimer’s disease – current concepts

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

Serum and cerebrospinal fluid neurofilament light chain in patients with central nervous system infections caused by varicella-zoster virus

Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the App NL−F/NL−F knock-in mouse model of Alzheimer’s disease

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment

Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer’s disease

Acute-Phase Neurofilament Light and Glial Fibrillary Acidic Proteins in Cerebrospinal Fluid Predict Long-Term Outcome After Severe Traumatic Brain Injury

Publisher Correction: Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies

Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies

Related objects

Reset password